A Trial of HRS-5965 Capsule in Primary IgA Nephropathy

Abroad (travel likely)RecruitingPHASE3

Conditions

Primary IgA Nephropathy

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Peking University First Hospital, Beijing, Beijing Municipality, China
Contact: Principal Investigator (Hong Zhang)

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression

Primary IgA Nephropathy

Abroad (travel likely)RecruitingPHASE3

Alabaster, United States · Birmingham, United States

A Study of SHR-2173 in Participants With Primary IgA Nephropathy

Primary IgA Nephropathy

Abroad (travel likely)RecruitingPHASE2

Guangzhou, China · Shanghai, China

Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN

Berger Disease · Bergers Disease · IgA Nephropathy

Abroad (travel likely)RecruitingPHASE3

Neptune City, United States · Cincinnati, United States

Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy

IgA Nephropathy

Abroad (travel likely)RecruitingPHASE4

Birmingham, United States · Glendale, United States